Questions around this news
What received the UK Promising Innovative Medicine designation, and for which condition?
The release says the UK Medicines and Healthcare products Regulatory Agency granted the designation to SGX945, also called dusquetide, an investigational therapy being developed by Soligenix for Behçet’s disease. It also says the UK recognition follows other regulatory recognitions for dusquetide, but does not identify those recognitions in the text provided.
What is a Promising Innovative Medicine designation?
A Promising Innovative Medicine designation is a UK regulatory recognition for a medicine considered to show promise in treating a serious or life-threatening condition. It is intended to identify a potential treatment early in development and can support discussions with regulators; it is not, by itself, marketing authorization or proof that the medicine is safe and effective.
Does a PIM designation mean a medicine is approved for patients?
No. A PIM designation is a regulatory recognition, not an approval to market or prescribe a medicine. The medicine must still undergo the relevant development and regulatory review. The designation alone does not establish that a treatment works, nor does it guarantee that it will become available to patients.
What is Behçet’s disease?
Behçet’s disease is a rare, long-term inflammatory disorder that can affect blood vessels and multiple parts of the body. Common features include recurring mouth sores and genital ulcers; some people also develop eye, skin, joint, or other organ problems. Its course and severity vary, and care is tailored to the symptoms and organs involved.
- Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.
- The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease.
- The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide.
Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its investigational therapy SGX945 was granted Promising Innovative Medicine (“PIM”) designation by the United Kingdom’s (“UK’s”) Medicines and Healthcare products Regulatory Agency (“MHRA”).
Designations granted by leading regulatory agencies play a critical role in advancing drug-development programs. These recognitions often signal that a therapy shows potential to address serious conditions where few treatment options exist. According to the UK MHRA, the PIM designation is awarded to…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Soligenix
- Ticker
- NASDAQ: SNGX
- Announcement
- Regulatory
- Location
- United Kingdom
